However, this problem may be overcome by new active drugs such as cabazitaxel. BMs should be distinguished from other CNS metastases. The term BM should be limited to the focal seeding of the ...
Cabazitaxel's recent FDA approval makes it a suitable option for patients with disease progression post-docetaxel. Recent improvements in overall survival with the use of abiraterone following ...
Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC). Rucaparib vs docetaxel (DTX) or second-generation androgen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback